TOLAK (fluorouracil) by Pfizer is nucleic acid synthesis inhibitors [moa]. First approved in 2015.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
TOLAK is a topical cream formulation of fluorouracil, a nucleoside metabolic inhibitor that suppresses nucleic acid synthesis. It is indicated for treatment of actinic keratosis and other skin lesions on the face and scalp. The drug works by inhibiting DNA and RNA synthesis in rapidly dividing cells, making it effective for destroying precancerous and cancerous skin lesions.
Product is at peak lifecycle with moderate competitive pressure (30%), indicating stable commercial demand but likely mature team structure with focus on market defense.
Nucleic Acid Synthesis Inhibitors
Nucleoside Metabolic Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo
Worked on TOLAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TOLAK offers stable career opportunity within an established Pfizer product at peak commercial maturity, with roles focused on market defense and physician/patient engagement rather than launch activity. The product's topical dermatology positioning attracts professionals interested in primary care and specialty dermatology channels with lower complexity than systemic oncology products.